Stay updated with breaking news from Eric Halioua. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Intermediary results of high dose PDC*lung01 combined with pembrolizumab show mild safety profile, immunological activity and promising tumor response in Non-Small Cell Lung Cancer patientsCombination of high dose PDC*lung01 with pembrolizumab in 19 evaluable patients resulted in objective response rate of 63.2% and...
LIÈGE, Belgium & GRENOBLE, France, April 08, 2024--PDC*line Pharma, a clinical-stage biotech company developing a new class of potent and scalable active immunotherapies for cancers, today announces the interim results from the last cohort of patients in its phase I/II clinical trial (PDC-LUNG-101, NCT03970746) with PDC*lung01.
Treatment with PDC*lung01 induces anti-tumor immune response in significant number of patients which appears to be enhanced by combination with pembrolizumab PDC*line Pharma, a clinical stage biotech
Preliminary results with PDC*lung01 in monotherapy and at low dose with pembrolizumab evoke acceptable safety profile, immunological activity and promising tumour response in Non-Small Cell Lung Cancer
PDC*line Pharma, a clinical stage biotech company developing cancer vaccines, has completed its Series B2 round of financing, raising a total of €17.5m (US$20.3m) with Belgian and South-Korean investors.